バイオマーカー市場 : 2029年までの世界予測

出版：MarketsandMarkets（マーケッツアンドマーケッツ）　出版年月：2024年4月

Biomarkers Market – Global Forecast to 2029

バイオマーカー市場 : 製品とサービス (消耗品、ソフトウェア)、タイプ (安全性、有効性)、研究領域、技術 (NGS、PCR、質量分析)、疾患 (がん、感染症)、用途 (診断、臨床研究) – 2029年までの世界予測
Biomarkers Market by Product & Service (Consumable, Software), Type (Safety, Efficacy), Research Area, Technology (NGS, PCR, Mass Spectrometry), Disease (Cancer, Infectious), Application (Diagnostics, Clinical Research) – Global Forecast to 2029

お問合せ・ご注文　　出版社・価格・納期について

Report Overview

The biomarkers market is expected to reach USD 93.8 billion in 2029 from USD 57.7 billion in 2024, at a CAGR of 10.2% during the forecast period.

バイオマーカー市場は、2024年の577億米ドルから2029年には938億米ドルに達すると予想されており、予測期間中のCAGRは10.2%です。

The growth of this market can be attributed to the advantage that these assay kits offer standardized and optimized protocols, facilitating accurate and efficient analysis of biomarkers in various biological samples, thus contributing significantly to diagnostic and research endeavors in healthcare. Further, advances in technologies such as genomics, proteomics, metabolomics, and next-generation sequencing have expanded the capabilities of biomarkers. This has led to the development of novel biomarkers with enhanced sensitivity, specificity, and predictive value.

“The predictive biomarkers segment accounted for the largest share by efficacy biomarkers in 2023.”

The biomarkers market by type is segmented into safety biomarkers, efficacy biomarkers, and validation biomarkers. In 2023, the predictive biomarkers segment accounted for the largest share of the efficacy biomarkers segment in the global biomarkers market. Factors such as these biomarkers help tailor treatment strategies to individual patients, maximizing the likelihood of a favorable response while minimizing potential adverse effects. Examples include genetic mutations that predict response to targeted therapies are driving the growth of this market.

“The Asia Pacific region is growing at the highest CAGR in the biomarkers market during the forecast period of 2024-2029.”

The Asia Pacific region is expected to grow at the highest growth rate during the forecast period. Various factors including the large patient pool undergoing advanced medical testing and policy programs to provide effective care to cancer patients are factors driving the high growth of the APAC market.
Increased research activities from pharmaceutical and biotechnology companies to develop novel drug therapies are expected to boost the growth of the biomarkers market in the Asia Pacific region. As the region continues to invest in drug development, there is a growing demand for biomarkers supporting drug discovery efforts.

The primary interviews conducted for this report can be categorized as follows:

•  By Respondent: Supply Side- 70% and Demand Side 30%
•  By Designation: C-level Executives – 55%, Director-level – 20%, and Others – 25%
•  By Region: North America -45%, Europe -20%, Asia-Pacific -20%, Latin America -10%, Middle East -3%, and Africa-2%.

List of Companies Profiled in the Report:

• F. Hoffmann-La Roche Ltd (Switzerland)
• Merck KGaA (Germany)
• Thermo Fisher Scientific Inc. (US)
• Abbott (US)
• QIAGEN (Netherlands)
• Revvity (US)
• Laboratory Corporation of America Holdings (US)
• Charles River Laboratories (US)
• Bio-Rad Laboratories, Inc. (US)
• Eurofins Scientific (Luxembourg)
• BIOMÉRIEUX (France)
• Agilent Technologies, Inc. (US)
• JSR Corporation (Japan)
• Quanterix (US)
• MESO SCALE DIAGNOSTICS, LLC. (US)
• EKF Diagnostics (UK)
• Celerion (US)
• Standard BioTools (US)
• Sebia (France)
• BioAgilytix Labs (US)
• StressMarq Biosciences Inc. (Canada)
• NorthEast BioAnalytical Laboratories LLC (US)
• Signosis, Inc. (US)
• Serimmune (US)
• TheraIndx Lifesciences Pvt. Ltd. (India)
• Synexa Life Sciences BV (Netherlands)
• Diatech Pharmacogenetics (Italy)
• Singulex, Inc. (US)
• R-Biopharm AG (Germany)
• Proteome Sciences (UK)

Research Coverage:

This research report categorizes the biomarkers market by product & service (consumables (assay kits, columns & filters, reagents & chemicals), services, and software), type (safety biomarkers, efficacy biomarkers (surrogate biomarkers, pharmacodynamics biomarkers, predictive biomarkers, and prognostic biomarkers), and validation biomarkers), research area (genomics, proteomics, metabolomics, and other research area), technology (immunoassays (western blot, ELISA, and protein microarray), NGS, PCR, mass spectrometry, chromatography, and other technologies), disease indication (cancer, infectious diseases, cardiovascular disorders, immunological disorders, neurological disorders, and other disease indications), application (clinical diagnostics, drug discovery & development, personalized medicines, clinical research, and other applications), end user (pharmaceutical & biotechnologies companies, hospitals & diagnostics laboratories, research & academic institutes, and other end users), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The report provides in-depth information on significant factors influencing the growth of the biomarkers market, including drivers, trends, challenges, and opportunities. A thorough analysis of major industry players has been undertaken to provide insights into their business profiles, products/services, key strategies, collaborations, partnerships, and agreements. Additionally, the report encompasses recent developments such as new product launches, and acquisitions within the biomarkers market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall biomarkers market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (Growing significance of biomarkers in drug discovery and development, Growing importance of companion diagnostics, Increase in global prevalence of cancer, Growing importance of biomarkers for rare conditions, Increase in funds and grants for biomarker research, Advancement in omics technologies and continuous product innovations), restraints (High capital investments and lengthy timelines for biomarker development, Disease complexity, and heterogeneity), opportunities (Shift towards personalized medicine and precision oncology, Enhanced collaboration among healthcare providers and key industry players, Emerging economies), and challenges (Challenges associated with quantification and validation of biomarkers, Challenges associated integration of complex data sets, Technical issues related to sample collection and storage) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on newly launched products/services of the biomarkers market
• Market Development: Comprehensive information about lucrative markets – the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products/services, untapped geographies, recent developments, and investments in the biomarkers market
• Competitive Assessment: F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), QIAGEN (Netherlands), Revvity (US), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), Eurofins Scientific (Luxembourg), BIOMÉRIEUX (France), Agilent Technologies, Inc. (US), JSR Corporation (Japan), Quanterix (US), MESO SCALE DIAGNOSTICS, LLC. (US), EKF Diagnostics (UK), Celerion (US), Standard BioTools (US), Sebia (France), BioAgilytix Labs (US), StressMarq Biosciences Inc. (Canada), NorthEast BioAnalytical Laboratories LLC (US), Signosis, Inc. (US), Serimmune (US), TheraIndx Lifesciences Pvt. Ltd. (India), Synexa Life Sciences BV (Netherlands), Diatech Pharmacogenetics (Italy), Singulex, Inc. (US), R-Biopharm AG (Germany), and Proteome Sciences (UK) among others in the market.

Table of Contents

1            INTRODUCTION            67

1.1         STUDY OBJECTIVES      67

1.2         MARKET DEFINITION   67

1.2.1      INCLUSIONS AND EXCLUSIONS 68

1.3         MARKET SCOPE             69

1.3.1      MARKETS COVERED     69

1.3.2      REGIONS COVERED      70

1.3.3      YEARS CONSIDERED     70

1.4         CURRENCY CONSIDERED          71

1.5         STAKEHOLDERS            71

1.6         SUMMARY OF CHANGES            71

1.6.1      RECESSION IMPACT      72

2            RESEARCH METHODOLOGY     73

2.1         RESEARCH DATA           73

FIGURE 1           RESEARCH DESIGN       73

2.1.1      SECONDARY DATA       74

2.1.2      PRIMARY DATA 74

FIGURE 2           BREAKDOWN OF PRIMARIES: BIOMARKERS MARKET    75

2.2         MARKET ESTIMATION METHODOLOGY            76

FIGURE 3           BIOMARKERS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023             76

2.2.1      GLOBAL MARKET ESTIMATION 76

FIGURE 4           MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023             77

FIGURE 5           ILLUSTRATIVE EXAMPLE OF HOFFMANN-LA ROCHE LTD.: REVENUE SHARE ANALYSIS (2023)         77

2.2.1.1   Insights of primary experts 79

FIGURE 6           MARKET SIZE VALIDATION FROM PRIMARY SOURCES  79

2.2.2      SEGMENTAL MARKET SIZE ESTIMATION           79

FIGURE 7           MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH       79

2.3         MARKET GROWTH RATE PROJECTIONS             80

FIGURE 8           BIOMARKERS MARKET (SUPPLY-SIDE): CAGR PROJECTIONS              81

TABLE 1             IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS           81

2.4         MARKET BREAKDOWN AND DATA TRIANGULATION    83

FIGURE 9           DATA TRIANGULATION METHODOLOGY         83

2.5         RESEARCH ASSUMPTIONS         84

2.6         LIMITATIONS   84

2.7         RISK ANALYSIS 85

2.8         RECESSION IMPACT ANALYSIS 85

3            EXECUTIVE SUMMARY 87

FIGURE 10         BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029 (USD MILLION) 87

FIGURE 11         BIOMARKERS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)              88

FIGURE 12         BIOMARKERS MARKET, BY RESEARCH AREA, 2024 VS. 2029 (USD MILLION)          88

FIGURE 13         BIOMARKERS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)          89

FIGURE 14         BIOMARKERS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)          89

FIGURE 15         GEOGRAPHICAL SNAPSHOT OF BIOMARKERS MARKET 90

4            PREMIUM INSIGHTS      91

4.1         BIOMARKERS MARKET OVERVIEW        91

FIGURE 16         ADVANCEMENTS IN OMICS TECHNOLOGIES AND RISING DRUG DISCOVERY & DEVELOPMENT ACTIVITIES TO PROPEL MARKET 91

4.2         ASIA PACIFIC: BIOMARKERS MARKET, BY PRODUCT & SERVICE 92

FIGURE 17         CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023 92

4.3         BIOMARKERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES              93

FIGURE 18         CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD              93

4.4         BIOMARKERS MARKET SHARE, BY END USER (2023)       93

FIGURE 19         PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD            93

5            MARKET OVERVIEW     94

5.1         INTRODUCTION            94

5.2         MARKET DYNAMICS     94

FIGURE 20         BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES    94

TABLE 2             BIOMARKERS MARKET: IMPACT ANALYSIS        95

5.2.1      DRIVERS            96

5.2.1.1   Increasing use of biomarkers in drug discovery & development  96

5.2.1.2   Growing importance of companion diagnostics            96

5.2.1.3   Rising prevalence of cancer 97

TABLE 3             CANCER INCIDENCE, BY REGION (2040)             97

5.2.1.4   Increasing development of biomarkers for rare diseases             98

5.2.1.5   Increasing funds and grants for biomarker research     98

5.2.1.6   Advancements in omics technologies             99

TABLE 4             PRODUCT APPROVALS & LAUNCHES (2022–2024)           100

5.2.2      RESTRAINTS     101

5.2.2.1   High capital investment and extensive timelines for biomarker development              101

TABLE 5             TIME FRAME FOR BIOMARKER DEVELOPMENT 101

5.2.2.2   Disease complexity and heterogeneity           101

5.2.3      OPPORTUNITIES           102

5.2.3.1   Growing preference for personalized medicine and precision oncology    102

5.2.3.2   Technological innovations between healthcare providers and key industry players              102

5.2.3.3   High growth potential of emerging economies             103

5.2.4      CHALLENGES   103

5.2.4.1   Issues associated with quantification & validation of biomarkers 103

5.2.4.2   Complexities associated with data set integration         104

5.2.4.3   Technical issues related to sample collection and storage           104

5.3         TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 105

FIGURE 21         TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES              106

5.4         REGULATORY LANDSCAPE       106

5.4.1      US         106

5.4.2      EUROPE             107

5.4.3      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS          107

TABLE 6             NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         107

TABLE 7             EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         108

TABLE 8             ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         110

TABLE 9             REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         112

5.5         VALUE CHAIN ANALYSIS            113

FIGURE 22         BIOMARKERS MARKET: VALUE CHAIN ANALYSIS           114

5.6         TECHNOLOGICAL ANALYSIS    115

5.6.1      KEY TECHNOLOGIES    115

5.6.1.1   Immunoassays     115

5.6.1.1.1 Immunohistochemistry (IHC)         115

5.6.1.1.2 ELISA   115

5.6.1.2   Next-generation Sequencing (NGS) 116

5.6.1.3   Polymerase Chain Reaction (PCR)  116

5.6.1.4   In Situ Hybridization         116

5.6.1.5   Microarrays         117

5.6.1.6   Mass Spectrometry            117

5.6.2      COMPLIMENTARY TECHNOLOGIES      117

5.6.2.1   Liquid Biopsy      117

5.6.2.2   CRISPR 118

5.6.3      ADJACENT TECHNOLOGIES      118

5.6.3.1   Artificial Intelligence (AI) and Machine Learning (ML)            118

5.6.3.2   Sensors (Wearable Devices)            118

5.7         PRICING ANALYSIS        119

5.7.1      AVERAGE SELLING PRICE OF BIOMARKERS CONSUMABLES      119

TABLE 10           AVERAGE SELLING PRICE OF BIOMARKERS BY KEY PLAYERS              119

5.7.2      AVERAGE SELLING PRICE OF BIOMARKERS CONSUMABLES      119

TABLE 11           AVERAGE SELLING PRICE OF BIOMARKERS BY REGION 119

5.8         PATENT ANALYSIS        120

5.8.1      METHODOLOGY           120

5.8.2      PATENTS FILED, BY DOCUMENT TYPE, 2014–2024          120

TABLE 12           PATENTS FILED, 2014–2024        120

5.8.3      INNOVATION AND PATENT APPLICATIONS      120

FIGURE 23         NUMBER OF PATENTS GRANTED IN THE PAST 10 YEARS              120

5.8.4      TOP APPLICANTS          121

FIGURE 24         TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS, 2014–2024         121

TABLE 13           TOP 20 PATENT OWNERS IN BIOMARKERS, 2014–2024    121

TABLE 14           INDICATIVE LIST OF PATENTS IN BIOMARKERS MARKET, 2022–2024      122

5.9         BIOMARKERS MARKET: SUPPLY CHAIN ANALYSIS          124

FIGURE 25         BIOMARKERS MARKET: SUPPLY CHAIN ANALYSIS          125

5.10       ECOSYSTEM ANALYSIS 125

FIGURE 26         BIOMARKERS MARKET: ECOSYSTEM ANALYSIS 125

5.10.1    BIOMARKER TESTING RAW MATERIAL SUPPLIERS         126

TABLE 15           BIOMARKERS MARKET: RAW MATERIAL SUPPLIERS      126

5.10.2    BIOMARKER TESTING PRODUCT VENDORS      126

TABLE 16           BIOMARKERS MARKET: PRODUCT VENDORS    126

5.10.3    BIOMARKER TESTING SERVICE PROVIDERS      127

TABLE 17           BIOMARKERS MARKET: SERVICE PROVIDERS    127

5.10.4    BIOMARKER TESTING END USERS         127

TABLE 18           BIOMARKERS MARKET: END USERS       127

5.10.5    BIOMARKER TESTING REGULATORY AUTHORITIES      128

TABLE 19           BIOMARKERS MARKET: REGULATORY AUTHORITIES    128

5.11       KEY CONFERENCES AND EVENTS, 2024–2025     128

TABLE 20           BIOMARKERS MARKET: LIST OF CONFERENCES AND EVENTS              128

5.12       KEY STAKEHOLDERS AND BUYING CRITERIA    130

5.12.1    KEY STAKEHOLDERS ON BUYING PROCESS       130

FIGURE 27         INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF BIOMARKERS    130

5.12.2    BIOMARKERS MARKET: BUYING CRITERIA         131

FIGURE 28         KEY BUYING CRITERIA FOR END USERS              131

TABLE 21           BUYING CRITERIA FOR BIOMARKER PRODUCTS, BY END USER              131

5.13       PORTER’S FIVE FORCES ANALYSIS         132

TABLE 22           IMPACT OF PORTER’S FIVE FORCES ON BIOMARKERS MARKET              132

5.13.1    INTENSITY OF COMPETITIVE RIVALRY 133

5.13.2    BARGAINING POWER OF SUPPLIERS     133

5.13.3    BARGAINING POWER OF BUYERS           133

5.13.4    THREAT OF SUBSTITUTES         133

5.13.5    THREAT OF NEW ENTRANTS    133

5.14       INVESTMENT AND FUNDING SCENARIO            134

TABLE 23           US: CANCER BIOMARKER FUNDING, 2021–2024 134

6            BIOMARKERS MARKET, BY PRODUCT & SERVICE            135

6.1         INTRODUCTION            136

TABLE 24           BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 136

6.2         CONSUMABLES 136

TABLE 25           CONSUMABLES MARKET, BY REGION, 2022–2029 (USD MILLION)          137

TABLE 26           NORTH AMERICA: CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          137

TABLE 27           EUROPE: CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 138

TABLE 28           ASIA PACIFIC: CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     138

TABLE 29           LATIN AMERICA: CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          139

TABLE 30           MIDDLE EAST: CONSUMABLES MARKET, BY REGION, 2022–2029 (USD MILLION)     139

TABLE 31           GCC COUNTRIES: CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          139

TABLE 32           CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)              140

6.2.1      ASSAY KITS       140

6.2.1.1   Usage in biomolecule detection, quantification, and characterization to boost demand 140

TABLE 33           ASSAY KITS MARKETS, BY REGION, 2022–2029 USD MILLION)              141

TABLE 34           NORTH AMERICA: ASSAY KITS MARKETS, BY COUNTRY, 2022–2029 (USD MILLION)     141

TABLE 35           EUROPE: ASSAY KITS MARKETS, BY COUNTRY, 2022–2029 (USD MILLION)          142

TABLE 36           ASIA PACIFIC: ASSAY KITS MARKETS, BY COUNTRY, 2022–2029 (USD MILLION) 142

TABLE 37           LATIN AMERICA: ASSAY KITS MARKETS, BY COUNTRY, 2022–2029 (USD MILLION)     142

TABLE 38           MIDDLE EAST: ASSAY KITS MARKETS, BY REGION, 2022–2029 (USD MILLION) 143

TABLE 39           GCC COUNTRIES: ASSAY KITS MARKETS, BY COUNTRY, 2022–2029 (USD MILLION)     143

6.2.2      REAGENTS & CHEMICALS          143

6.2.2.1   Recurrent usage in drug discovery & development to boost demand         143

TABLE 40           REAGENTS & CHEMICALS MARKET, BY REGION, 2022–2029 (USD MILLION) 144

TABLE 41           NORTH AMERICA: REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    145

TABLE 42           EUROPE: REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          145

TABLE 43           ASIA PACIFIC: REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    146

TABLE 44           LATIN AMERICA: REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    146

TABLE 45           MIDDLE EAST: REAGENTS & CHEMICALS MARKET, BY REGION, 2022–2029 (USD MILLION)          146

TABLE 46           GCC COUNTRIES: REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    147

6.2.3      COLUMNS & FILTERS    147

6.2.3.1   High uptake across end-user facilities to support market growth 147

TABLE 47           COLUMNS & FILTERS MARKET, BY REGION, 2022–2029 (USD MILLION)          148

TABLE 48           NORTH AMERICA: COLUMNS & FILTERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    148

TABLE 49           EUROPE: COLUMNS & FILTERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     148

TABLE 50           ASIA PACIFIC: COLUMNS & FILTERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          149

TABLE 51           LATIN AMERICA: COLUMNS & FILTERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          149

TABLE 52           MIDDLE EAST: COLUMNS & FILTERS MARKET, BY REGION, 2022–2029 (USD MILLION)          149

TABLE 53           GCC COUNTRIES: COLUMNS & FILTERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    150

6.3         SERVICES          150

6.3.1      INCREASING NUMBER OF CROS TO DRIVE MARKET      150

TABLE 54           BIOMARKER SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)          151

TABLE 55           NORTH AMERICA: BIOMARKER SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    152

TABLE 56           EUROPE: BIOMARKER SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     152

TABLE 57           ASIA PACIFIC: BIOMARKER SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          152

TABLE 58           LATIN AMERICA: BIOMARKER SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    153

TABLE 59           MIDDLE EAST: BIOMARKER SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)          153

TABLE 60           GCC COUNTRIES: BIOMARKER SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    153

6.4         SOFTWARE       154

6.4.1      INCREASING ADOPTION OF BIOINFORMATICS TOOLS TO DRIVE MARKET            154

TABLE 61           SOFTWARE MARKET, BY REGION, 2022–2029 (USD MILLION)              154

TABLE 62           NORTH AMERICA: SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     155

TABLE 63           EUROPE: SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          155

TABLE 64           ASIA PACIFIC: SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 155

TABLE 65           LATIN AMERICA: SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     156

TABLE 66           MIDDLE EAST: SOFTWARE MARKET, BY REGION,2022–2029 (USD MILLION) 156

TABLE 67           GCC COUNTRIES: SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     156

7            BIOMARKERS MARKET, BY TYPE            157

7.1         INTRODUCTION            158

TABLE 68           BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)              158

7.2         SAFETY BIOMARKERS   158

7.2.1      ABILITY TO MEASURE ADVERSE EFFECTS TO PROPEL MARKET 158

TABLE 69           SAFETY BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION)          159

TABLE 70           NORTH AMERICA: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    159

TABLE 71           EUROPE: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     160

TABLE 72           ASIA PACIFIC: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          160

TABLE 73          LATIN AMERICA: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          161

TABLE 74           MIDDLE EAST: SAFETY BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION)          161

TABLE 75           GCC COUNTRIES: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    161

7.3         EFFICACY BIOMARKERS             162

TABLE 76           EFFICACY BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION)          162

TABLE 77           NORTH AMERICA: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    162

TABLE 78           EUROPE: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          163

TABLE 79           ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          163

TABLE 80           LATIN AMERICA: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    164

TABLE 81           MIDDLE EAST: EFFICACY BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION)          164

TABLE 82           GCC COUNTRIES: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    164

TABLE 83           EFFICACY BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)          165

7.3.1      PREDICTIVE BIOMARKERS        165

7.3.1.1   Ease of patient identification to support market growth             165

TABLE 84           PREDICTIVE BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION) 166

TABLE 85           NORTH AMERICA: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    166

TABLE 86           EUROPE: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          167

TABLE 87           ASIA PACIFIC: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    167

TABLE 88           LATIN AMERICA: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    168

TABLE 89           MIDDLE EAST: PREDICTIVE BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION)       168

TABLE 90           GCC COUNTRIES: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    168

7.3.2      SURROGATE BIOMARKERS        169

7.3.2.1   Ease of tracking treatment effectiveness to drive adoption         169

TABLE 91           SURROGATE BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION) 169

TABLE 92           NORTH AMERICA: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    170

TABLE 93           EUROPE: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          170

TABLE 94           ASIA PACIFIC: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    170

TABLE 95           LATIN AMERICA: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    171

TABLE 96           MIDDLE EAST: SURROGATE BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION)       171

TABLE 97           GCC COUNTRIES: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    171

7.3.3      PHARMACODYNAMIC BIOMARKERS     172

7.3.3.1   High uptake in selection and optimization of drug doses to drive market  172

TABLE 98           PHARMACODYNAMIC BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION)          172

TABLE 99           NORTH AMERICA: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)         173

TABLE 100         EUROPE: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    173

TABLE 101         ASIA PACIFIC: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)            173

TABLE 102        LATIN AMERICA: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)            174

TABLE 103         MIDDLE EAST: PHARMACODYNAMIC BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION)  174

TABLE 104         GCC COUNTRIES: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)         174

7.3.4      PROGNOSTIC BIOMARKERS      175

7.3.4.1   Ability to predict health outcomes without therapeutic intervention to propel adoption 175

TABLE 105         PROGNOSTIC BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION) 175

TABLE 106         NORTH AMERICA: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    176

TABLE 107         EUROPE: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          176

TABLE 108         ASIA PACIFIC: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    176

TABLE 109         LATIN AMERICA: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    177

TABLE 110         MIDDLE EAST: PROGNOSTIC BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION)       177

TABLE 111         GCC COUNTRIES: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    177

7.4         VALIDATION BIOMARKERS       178

7.4.1      INCREASING ADOPTION BY REGULATORY AGENCIES FOR THERAPEUTIC COMMERCIALIZATION TO DRIVE MARKET        178

TABLE 112         VALIDATION BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION) 178

TABLE 113         NORTH AMERICA: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    179

TABLE 114         EUROPE: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          179

TABLE 115         ASIA PACIFIC: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    179

TABLE 116         LATIN AMERICA: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    180

TABLE 117         MIDDLE EAST: VALIDATION BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION)       180

TABLE 118         GCC COUNTRIES: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    180

8            BIOMARKERS MARKET, BY RESEARCH AREA      181

8.1         INTRODUCTION            182

TABLE 119         BIOMARKERS MARKET, BY RESEARCH AREA, 2022–2029 (USD MILLION)          182

8.2         GENOMICS        182

8.2.1      RISING TECHNOLOGICAL ADVANCEMENTS FOR BIOMARKER TESTING TO PROPEL MARKET 182

TABLE 120         BIOMARKERS MARKET FOR GENOMICS, BY REGION, 2022–2029 (USD MILLION) 183

TABLE 121         NORTH AMERICA: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2022–2029 (USD MILLION)    183

TABLE 122         EUROPE: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2022–2029 (USD MILLION)    184

TABLE 123         ASIA PACIFIC: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2022–2029 (USD MILLION)    184

TABLE 124         LATIN AMERICA: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2022–2029 (USD MILLION)    185

TABLE 125         MIDDLE EAST: BIOMARKERS MARKET FOR GENOMICS, BY REGION, 2022–2029 (USD MILLION)       185

TABLE 126         GCC COUNTRIES: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2022–2029 (USD MILLION)    185

8.3         PROTEOMICS   186

8.3.1      RISING INCIDENCE OF CHRONIC DISEASES TO BOOST DEMAND              186

TABLE 127         BIOMARKERS MARKET FOR PROTEOMICS, BY REGION, 2022–2029 (USD MILLION)     186

TABLE 128         NORTH AMERICA: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2022–2029 (USD MILLION)            187

TABLE 129         EUROPE: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2022–2029 (USD MILLION)    187

TABLE 130         ASIA PACIFIC: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2022–2029 (USD MILLION)    188

TABLE 131         LATIN AMERICA: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2022–2029 (USD MILLION)    188

TABLE 132         MIDDLE EAST: BIOMARKERS MARKET FOR PROTEOMICS, BY REGION, 2022–2029 (USD MILLION)       188

TABLE 133         GCC COUNTRIES: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2022–2029 (USD MILLION)            189

8.4         METABOLOMICS           189

8.4.1      RISING INCIDENCE OF DIABETES AND OBESITY-RELATED CONDITIONS TO SUPPORT MARKET GROWTH 189

TABLE 134         BIOMARKERS MARKET FOR METABOLOMICS, BY REGION, 2022–2029 (USD MILLION)          190

TABLE 135         NORTH AMERICA: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2022–2029 (USD MILLION)        190

TABLE 136         EUROPE: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2022–2029 (USD MILLION)    190

TABLE 137         ASIA PACIFIC: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2022–2029 (USD MILLION)            191

TABLE 138        LATIN AMERICA: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2022–2029 (USD MILLION)            191

TABLE 139         MIDDLE EAST: BIOMARKERS MARKET FOR METABOLOMICS, BY REGION, 2022–2029 (USD MILLION)  191

TABLE 140         GCC COUNTRIES: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2022–2029 (USD MILLION)        192

8.5         OTHER RESEARCH AREAS          192

TABLE 141         BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY REGION, 2022–2029 (USD MILLION)       192

TABLE 142         NORTH AMERICA: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2022–2029 (USD MILLION)      193

TABLE 143         EUROPE: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2022–2029 (USD MILLION)             193

TABLE 144         ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2022–2029 (USD MILLION)             194

TABLE 145         LATIN AMERICA: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2022–2029 (USD MILLION)      194

TABLE 146         MIDDLE EAST: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY REGION, 2022–2029 (USD MILLION)  194

TABLE 147         GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2022–2029 (USD MILLION)      195

9            BIOMARKERS MARKET, BY TECHNOLOGY         196

9.1         INTRODUCTION            197

TABLE 148         BIOMARKERS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)          197

9.2         IMMUNOASSAYS            197

TABLE 149         IMMUNOASSAYS MARKET, BY TYPE, 2022–2029 (USD MILLION)              198

TABLE 150         IMMUNOASSAYS MARKET, BY REGION, 2022–2029 (USD MILLION)          198

TABLE 151         NORTH AMERICA: IMMUNOASSAYS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          198

TABLE 152         EUROPE: IMMUNOASSAYS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 199

TABLE 153         ASIA PACIFIC: IMMUNOASSAYS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     199

TABLE 154         LATIN AMERICA: IMMUNOASSAYS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          200

TABLE 155         MIDDLE EAST: IMMUNOASSAYS MARKET, BY REGION, 2022–2029 (USD MILLION)     200

TABLE 156         GCC COUNTRIES: IMMUNOASSAYS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          200

9.2.1      ELISA   201

9.2.1.1   ELISA to hold largest market share  201

TABLE 157         ELISA MARKET, BY REGION, 2022–2029 (USD MILLION) 202

TABLE 158         NORTH AMERICA: ELISA MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 202

TABLE 159         EUROPE: ELISA MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          202

TABLE 160         ASIA PACIFIC: ELISA MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          203

TABLE 161         LATIN AMERICA: ELISA MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 203

TABLE 162         MIDDLE EAST: ELISA MARKET, BY REGION, 2022–2029 (USD MILLION)          203

TABLE 163         GCC COUNTRIES: ELISA MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 204

9.2.2      PROTEIN MICROARRAYS            204

9.2.2.1   Cost efficIency and high sensitivity to propel adoption 204

TABLE 164         PROTEIN MICROARRAYS MARKET, BY REGION, 2022–2029 (USD MILLION)          205

TABLE 165         NORTH AMERICA: PROTEIN MICROARRAYS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    205

TABLE 166         EUROPE: PROTEIN MICROARRAYS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          206

TABLE 167        ASIA PACIFIC: PROTEIN MICROARRAYS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          206

TABLE 168         LATIN AMERICA: PROTEIN MICROARRAYS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    207

TABLE 169         MIDDLE EAST: PROTEIN MICROARRAYS MARKET, BY REGION, 2022–2029 (USD MILLION)          207

TABLE 170         GCC COUNTRIES: PROTEIN MICROARRAYS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    207

9.2.3      WESTERN BLOT             208

9.2.3.1   Increasing utilization in translation medicine to drive market     208

TABLE 171         WESTERN BLOT MARKET, BY REGION, 2022–2029 (USD MILLION)          208

TABLE 172         NORTH AMERICA: WESTERN BLOT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          208

TABLE 173         EUROPE: WESTERN BLOT MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 208

TABLE 174         ASIA PACIFIC: WESTERN BLOT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     209

TABLE 175         LATIN AMERICA: WESTERN BLOT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          210

TABLE 176         MIDDLE EAST: WESTERN BLOT MARKET, BY REGION, 2022–2029 (USD MILLION)     210

TABLE 177         GCC COUNTRIES: WESTERN BLOT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          210

9.3         NGS      211

9.3.1      TECHNOLOGICAL ADVANCEMENTS IN NGS PLATFORMS TO BOOST DEMAND           211

TABLE 178         NGS MARKET, BY REGION, 2022–2029 (USD MILLION)    212

TABLE 179         NORTH AMERICA: NGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          212

TABLE 180         EUROPE: NGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          212

TABLE 181         ASIA PACIFIC: NGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          213

TABLE 182         LATIN AMERICA: NGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          213

TABLE 183         MIDDLE EAST: NGS MARKET, BY REGION, 2022–2029 (USD MILLION)          213

TABLE 184         GCC COUNTRIES: NGS MARKET, 2022–2029 (USD MILLION)              214

9.4         PCR       214

9.4.1      RAPID AND SENSITIVE DETECTION OF GENETIC BIOMARKERS TO DRIVE MARKET 214

TABLE 185         PCR MARKET, BY REGION, 2022–2029 (USD MILLION)    215

TABLE 186         NORTH AMERICA: PCR MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          215

TABLE 187         EUROPE: PCR MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          215

TABLE 188         ASIA PACIFIC: PCR MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          216

TABLE 189         LATIN AMERICA: PCR MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          216

TABLE 190         MIDDLE EAST: PCR MARKET, BY REGION, 2022–2029 (USD MILLION)          216

TABLE 191         GCC COUNTRIES: PCR MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          217

9.5         MASS SPECTROMETRY 217

9.5.1      INTEGRATION WITH OMICS TECHNOLOGIES TO DRIVE MARKET              217

TABLE 192         MASS SPECTROMETRY MARKET, BY REGION, 2022–2029 (USD MILLION)          218

TABLE 193         NORTH AMERICA: MASS SPECTROMETRY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    218

TABLE 194         EUROPE: MASS SPECTROMETRY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     218

TABLE 195         ASIA PACIFIC: MASS SPECTROMETRY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          219

TABLE 196         LATIN AMERICA: MASS SPECTROMETRY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    219

TABLE 197         MIDDLE EAST: MASS SPECTROMETRY MARKET, BY REGION, 2022–2029 (USD MILLION)          219

TABLE 198         GCC COUNTRIES: MASS SPECTROMETRY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    220

9.6         CHROMATOGRAPHY    220

9.6.1      UTILIZATION IN PROTEOMICS RESEARCH TO SUPPORT MARKET GROWTH          220

TABLE 199         CHROMATOGRAPHY MARKET, BY REGION, 2022–2029 (USD MILLION)          221

TABLE 200         NORTH AMERICA: CHROMATOGRAPHY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    221

TABLE 201         EUROPE: CHROMATOGRAPHY MARKET, BY COUNTRY,2022–2029 (USD MILLION)     221

TABLE 202         ASIA PACIFIC: CHROMATOGRAPHY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          222

TABLE 203         LATIN AMERICA: CHROMATOGRAPHY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          222

TABLE 204         MIDDLE EAST: CHROMATOGRAPHY MARKET, BY REGION, 2022–2029 (USD MILLION)          222

TABLE 205         GCC COUNTRIES: CHROMATOGRAPHY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    223

9.7         OTHER TECHNOLOGIES            223

TABLE 206         OTHER TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)          224

TABLE 207         NORTH AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    224

TABLE 208         EUROPE: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          224

TABLE 209        ASIA PACIFIC: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          225

TABLE 210         LATIN AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    225

TABLE 211         MIDDLE EAST: OTHER TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)          225

TABLE 212         GCC COUNTRIES: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)    226

10          BIOMARKERS MARKET, BY DISEASE INDICATION           227

10.1       INTRODUCTION            228

TABLE 213         BIOMARKERS MARKET, BY DISEASE INDICATION, 2022–2029 (USD MILLION) 228

10.2       CANCER             228

10.2.1    RISING INCIDENCE OF CANCER AND GROWING FOCUS ON EARLY DISEASE DETECTION TO PROPEL MARKET       228

TABLE 214         LIST OF FDA-APPROVED BIOMARKERS FOR CANCER, BY TYPE              229

TABLE 215         BIOMARKERS MARKET FOR CANCER, BY REGION, 2022–2029 (USD MILLION) 230

TABLE 216         NORTH AMERICA: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)    230

TABLE 217         EUROPE: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)          230

TABLE 218         ASIA PACIFIC: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)    231

TABLE 219         LATIN AMERICA: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)    231

TABLE 220         MIDDLE EAST: BIOMARKERS MARKET FOR CANCER, BY REGION, 2022–2029 (USD MILLION)       231

TABLE 221         GCC COUNTRIES: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)    232

10.3       INFECTIOUS DISEASES 232

10.3.1    INCREASING INCIDENCE OF HIV AND TB TO BOOST DEMAND 232

TABLE 222         BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION)       233

TABLE 223         NORTH AMERICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)       233

TABLE 224         EUROPE: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)            234

TABLE 225         ASIA PACIFIC: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)       234

TABLE 226         LATIN AMERICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)       235

TABLE 227         MIDDLE EAST: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION)           235

TABLE 228         GCC COUNTRIES: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)       235

10.4       IMMUNOLOGICAL DISORDERS 236

10.4.1    RISING ADOPTION OF ASSAYS FOR AUTOIMMUNE DISEASE DETECTION TO DRIVE MARKET            236

TABLE 229         BIOMARKERS FOR IMMUNOLOGICAL DISORDERS         236

TABLE 230         BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2022–2029 (USD MILLION)       237

TABLE 231         NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)              237

TABLE 232         EUROPE: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)   238

TABLE 233         ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)   238

TABLE 234         LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)              239

TABLE 235         MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2022–2029 (USD MILLION)       239

TABLE 236         GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)              239

10.5       NEUROLOGICAL DISORDERS    240

10.5.1    HIGH UPTAKE OF ELISA FOR DIAGNOSIS TO SUPPORT MARKET GROWTH          240

TABLE 237         BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2022–2029 (USD MILLION)       240

TABLE 238         NORTH AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 241

TABLE 239         EUROPE: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)   241

TABLE 240         ASIA PACIFIC: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)   242

TABLE 241         LATIN AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)   242

TABLE 242         MIDDLE EAST: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2022–2029 (USD MILLION)       242

TABLE 243         GCC COUNTRIES: BIOMARKERS MARKET FOR CANCER, BY NEUROLOGICAL DISORDERS, 2022–2029 (USD MILLION)            243

10.6       CARDIOVASCULAR DISORDERS 243

10.6.1    TECHNOLOGICAL ADVANCEMENTS IN CARDIAC BIOMARKERS TO BOOST DEMAND           243

TABLE 244         BIOMARKERS FOR CARDIOVASCULAR DISORDERS        244

TABLE 245         BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2022–2029 (USD MILLION)  244

TABLE 246         NORTH AMERICA: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)              245

TABLE 247         EUROPE: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)   245

TABLE 248         ASIA PACIFIC: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)   246

TABLE 249         LATIN AMERICA: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)              246

TABLE 250         MIDDLE EAST: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2022–2029 (USD MILLION)       246

TABLE 251         GCC COUNTRIES: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)              247

10.7       OTHER DISEASE INDICATIONS 247

TABLE 252         BIOMARKERS FOR RENAL DISORDERS  248

TABLE 253         BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2022–2029 (USD MILLION)       248

TABLE 254         NORTH AMERICA: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)             249

TABLE 255         EUROPE: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)             249

TABLE 256         ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)             250

TABLE 257         LATIN AMERICA: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)             250

TABLE 258         MIDDLE EAST: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2022–2029 (USD MILLION)   250

TABLE 259         GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)             251

11          BIOMARKERS MARKET, BY APPLICATION          252

11.1       INTRODUCTION            253

TABLE 260         BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)          253

11.2       CLINICAL DIAGNOSTICS            253

11.2.1    GROWING FOCUS ON EARLY DISEASE DETECTION AND DIAGNOSIS TO BOOST DEMAND     253

TABLE 261         BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2022–2029 (USD MILLION)       254

TABLE 262         NORTH AMERICA: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)             254

TABLE 263         EUROPE: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)            255

TABLE 264         ASIA PACIFIC: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)             255

TABLE 265         LATIN AMERICA: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)             256

TABLE 266         MIDDLE EAST: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2022–2029 (USD MILLION)  256

TABLE 267         GCC COUNTRIES: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)             256

11.3       DRUG DISCOVERY & DEVELOPMENT    257

11.3.1    RISING FOCUS ON COST REDUCTION AND TREATMENT EFFICACY TO PROPEL MARKET          257

TABLE 268         BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2022–2029 (USD MILLION) 258

TABLE 269         NORTH AMERICA: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2022–2029 (USD MILLION)              258

TABLE 270         EUROPE: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2022–2029 (USD MILLION)          259

TABLE 271         ASIA PACIFIC: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2022–2029 (USD MILLION)          259

TABLE 272         LATIN AMERICA: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2022–2029 (USD MILLION)              260

TABLE 273         MIDDLE EAST: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2022–2029 (USD MILLION)          260

TABLE 274         GCC COUNTRIES: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2022–2029 (USD MILLION)              260

11.4       PERSONALIZED MEDICINE        261

11.4.1    GROWING PREFERENCE FOR THERAPEUTICS TO DRIVE MARKET              261

TABLE 275         LIST OF KEY PERSONALIZED MEDICINES AND RELEVANT BIOMARKERS    261

TABLE 276         BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2022–2029 (USD MILLION)       262

TABLE 277         NORTH AMERICA: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2022–2029 (USD MILLION)     262

TABLE 278         EUROPE: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2022–2029 (USD MILLION)     263

TABLE 279         ASIA PACIFIC: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2022–2029 (USD MILLION)     263

TABLE 280         LATIN AMERICA: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2022–2029 (USD MILLION)     264

TABLE 281         MIDDLE EAST: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2022–2029 (USD MILLION)         264

TABLE 282         GCC COUNTRIES: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2022–2029 (USD MILLION)     264

11.5       CLINICAL RESEARCH    265

11.5.1    INCREASING NUMBER OF CLINICAL TRIALS TO SUPPORT MARKET GROWTH          265

TABLE 283         NUMBER OF REGISTERED AND RECRUITING CLINICAL STUDIES, BY LOCATION             265

TABLE 284         BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY REGION, 2022–2029 (USD MILLION)          266

TABLE 285         NORTH AMERICA: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2022–2029 (USD MILLION)     266

TABLE 286         EUROPE: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2022–2029 (USD MILLION)    267

TABLE 287         ASIA PACIFIC: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2022–2029 (USD MILLION)     267

TABLE 288         LATIN AMERICA: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2022–2029 (USD MILLION)     268

TABLE 289         MIDDLE EAST: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY REGION, 2022–2029 (USD MILLION)         268

TABLE 290         GCC COUNTRIES: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2022–2029 (USD MILLION)     268

11.6       OTHER APPLICATIONS 269

TABLE 291         BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)       269

TABLE 292         NORTH AMERICA: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)           269

TABLE 293         EUROPE: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)            270

TABLE 294         ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)           270

TABLE 295         LATIN AMERICA: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)           271

TABLE 296         MIDDLE EAST: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION) 271

TABLE 297         GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)           271

12          BIOMARKERS MARKET, BY END USER    272

12.1       INTRODUCTION            273

TABLE 298         BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)          273

12.2       PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES   273

12.2.1    RISING DRUG DISCOVERY ACTIVITIES FOR NOVEL BIOMARKERS TO PROPEL MARKET          273

TABLE 299         PHARMA & BIOTECH SECTOR: RECENT DEVELOPMENTS              274

TABLE 300         BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION) 275

TABLE 301         NORTH AMERICA: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 275

TABLE 302         EUROPE: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)              276

TABLE 303         ASIA PACIFIC: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)              276

TABLE 304         LATIN AMERICA: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 277

TABLE 305         MIDDLE EAST: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION)              277

TABLE 306         GCC COUNTRIES: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 277

12.3       HOSPITALS & DIAGNOSTIC LABORATORIES      278

12.3.1    UPTAKE OF IMAGING BIOMARKERS IN CLINICAL SETTINGS TO BOOST DEMAND           278

TABLE 307         BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2022–2029 (USD MILLION) 279

TABLE 308         NORTH AMERICA: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)              279

TABLE 309         EUROPE: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)              280

TABLE 310         ASIA PACIFIC: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)              280

TABLE 311         LATIN AMERICA: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)              281

TABLE 312         MIDDLE EAST: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2022–2029 (USD MILLION)   281

TABLE 313         GCC COUNTRIES: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)              281

12.4       ACADEMIC & RESEARCH INSTITUTES   282

12.4.1    RISING FOCUS ON STEM CELL AND CANCER RESEARCH TO SUPPORT MARKET GROWTH        282

TABLE 314         BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION)      283

TABLE 315         NORTH AMERICA: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)          283

TABLE 316         EUROPE: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)  284

TABLE 317         ASIA PACIFIC: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)          284

TABLE 318         LATIN AMERICA: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)          285

TABLE 319         MIDDLE EAST: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION) 285

TABLE 320         GCC COUNTRIES: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)          285

12.5       OTHER END USERS        286

TABLE 321         BIOMARKERS MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)          286

TABLE 322         NORTH AMERICA: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)             287

TABLE 323         EUROPE: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)    287

TABLE 324         ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)            288

TABLE 325         LATIN AMERICA: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)             288

TABLE 326         MIDDLE EAST: BIOMARKERS MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)  288

TABLE 327         GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)             289

13          BIOMARKERS MARKET, BY REGION       290

13.1       INTRODUCTION            291

TABLE 328         BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION)              291

13.2       NORTH AMERICA          291

13.2.1    NORTH AMERICA: RECESSION IMPACT 292

FIGURE 29         NORTH AMERICA: BIOMARKERS MARKET SNAPSHOT   292

TABLE 329         NORTH AMERICA: BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     293

TABLE 330         NORTH AMERICA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)       293

TABLE 331         NORTH AMERICA: CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)     293

TABLE 332         NORTH AMERICA: BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 294

TABLE 333         NORTH AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)          294

TABLE 334         NORTH AMERICA: BIOMARKERS MARKET, BY RESEARCH AREA, 2022–2029 (USD MILLION)          294

TABLE 335         NORTH AMERICA: BIOMARKERS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)          295

TABLE 336         NORTH AMERICA: IMMUNOASSAYS MARKET, BY TYPE, 2022–2029 (USD MILLION)     295

TABLE 337         NORTH AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022–2029 (USD MILLION)             296

TABLE 338         NORTH AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)          296

TABLE 339         NORTH AMERICA: BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)     297

13.2.2    US         297

13.2.2.1 Rising focus on biopharma research to propel market   297

FIGURE 30         NIH FUNDING MEDICAL RESEARCH IN 10 YEARS (2014–2024)              298

TABLE 340         US: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 298

TABLE 341         US: CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)          299

TABLE 342         US: BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)              299

TABLE 343         US: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)          299

TABLE 344         US: BIOMARKERS MARKET, BY RESEARCH AREA, 2022–2029 (USD MILLION) 300

TABLE 345         US: BIOMARKERS MARKET, BY TECHNOLOGY, 2022–2029 USD MILLION)          300

TABLE 346         US: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)          300

TABLE 347         US: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022–2029 (USD MILLION)     301

TABLE 348         US: BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)          301

TABLE 349         US: BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)          302

13.2.3    CANADA            302

13.2.3.1 Increasing incidence of cancer to boost demand for biomarker discovery 302

TABLE 350         CANADA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)          303

TABLE 351         CANADA: CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)          303

TABLE 352         CANADA: BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)          303

TABLE 353         CANADA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)     304

TABLE 354         CANADA: BIOMARKERS MARKET, BY RESEARCH AREA, 2022–2029 (USD MILLION)     304

TABLE 355         CANADA: BIOMARKERS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 304

TABLE 356         CANADA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)             305

TABLE 357         CANADA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022–2029 (USD MILLION)          305

TABLE 358         CANADA: BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 305

TABLE 359         CANADA: BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION) 306

13.3       EUROPE             306

13.3.1    EUROPE: RECESSION IMPACT   306

TABLE 360         EUROPE: BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 307

TABLE 361         EUROPE: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)          307

TABLE 362         EUROPE: CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)          308

TABLE 363         EUROPE: BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)          308

TABLE 364         EUROPE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 308

TABLE 365         EUROPE: BIOMARKERS MARKET, BY RESEARCH AREA, 2022–2029 (USD MILLION)     309

TABLE 366         EUROPE: BIOMARKERS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 309

TABLE 367         EUROPE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)             309

TABLE 368         EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022–2029 (USD MILLION)          310

TABLE 369         EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 310

TABLE 370         EUROPE: BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)          311

13.3.2    GERMANY         311

13.3.2.1 Growth in biopharmaceutical R&D activities to propel market   311

TABLE 371         GERMANY: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)          312

TABLE 372         GERMANY: CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)          312

TABLE 373         GERMANY: BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)          312

TABLE 374         GERMANY: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)     313

TABLE 375         GERMANY: BIOMARKERS MARKET, BY RESEARCH AREA, 2022–2029 (USD MILLION)     313

TABLE 376         GERMANY: BIOMARKERS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)     313

TABLE 377         GERMANY: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)             314

TABLE 378         GERMANY: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022–2029 (USD MILLION)          314

TABLE 379         GERMANY: BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)     314

TABLE 380         GERMANY: BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION) 315

13.3.3    UK         315

13.3.3.1 Government funding and strategic collaborations with biotech firms to drive market   315

TABLE 381         UK: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 315

TABLE 382         UK: CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)          316

TABLE 383         UK: BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)              316

TABLE 384         UK: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)          316

TABLE 385         UK: BIOMARKERS MARKET, BY RESEARCH AREA, 2022–2029 (USD MILLION) 317

TABLE 386         UK: BIOMARKERS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)          317

TABLE 387         UK: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)          317

TABLE 388         UK: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022–2029 (USD MILLION)     318

TABLE 389         UK: BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)          318

TABLE 390         UK: BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)          319

13.3.4    FRANCE             319

13.3.4.1 Rising funding for proteomics & genomics research to drive market         319

TABLE 391         FRANCE: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)          320

TABLE 392         FRANCE: CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)          320

TABLE 393         FRANCE: BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)          320

TABLE 394         FRANCE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 321

TABLE 395         FRANCE: BIOMARKERS MARKET, BY RESEARCH AREA, 2022–2029 (USD MILLION)     321

TABLE 396         FRANCE: BIOMARKERS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 321

TABLE 397         FRANCE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)             322

TABLE 398         FRANCE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022–2029 (USD MILLION)          322

TABLE 399         FRANCE: BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 323

TABLE 400         FRANCE: BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)          323

13.3.5    ITALY   323

13.3.5.1 Increasing developments in life sciences research to fuel market 323

TABLE 401         ITALY: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)     324

TABLE 402         ITALY: CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)          324

TABLE 403         ITALY: BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)          324

TABLE 404         ITALY: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 325

TABLE 405         ITALY: BIOMARKERS MARKET, BY RESEARCH AREA, 2022–2029 (USD MILLION) 325

TABLE 406         ITALY: BIOMARKERS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 325

TABLE 407         ITALY: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)          326

TABLE 408         ITALY: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022–2029 (USD MILLION)     326

TABLE 409         ITALY: BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 326

TABLE 410         ITALY: BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)          327

13.3.6    SPAIN   327

13.3.6.1 R&D initiatives for personalized medicine to support market growth       327

TABLE 411         SPAIN: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)     328

TABLE 412         SPAIN: CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)          328

TABLE 413         SPAIN: BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)          328

TABLE 414         SPAIN: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 329

TABLE 415         SPAIN: BIOMARKERS MARKET, BY RESEARCH AREA, 2022–2029 (USD MILLION) 329

TABLE 416         SPAIN: BIOMARKERS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 329

TABLE 417         SPAIN: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)          330

TABLE 418         SPAIN: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022–2029 (USD MILLION)     330

TABLE 419         SPAIN: BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 330

TABLE 420         SPAIN: BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)          331

13.3.7    REST OF EUROPE           331

TABLE 421         REST OF EUROPE: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)       332

TABLE 422         REST OF EUROPE: CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)     332

TABLE 423         REST OF EUROPE: BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 332

TABLE 424         REST OF EUROPE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)          333

TABLE 425         REST OF EUROPE: BIOMARKERS MARKET, BY RESEARCH AREA, 2022–2029 (USD MILLION)          333

TABLE 426         REST OF EUROPE: BIOMARKERS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)          333

TABLE 427         REST OF EUROPE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)   334

TABLE 428         REST OF EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022–2029 (USD MILLION)             334

TABLE 429         REST OF EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)          335

TABLE 430         REST OF EUROPE: BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)     335

13.4       ASIA PACIFIC    336

13.4.1    ASIA PACIFIC: RECESSION IMPACT        336

FIGURE 31         ASIA PACIFIC: BIOMARKERS MARKET SNAPSHOT           337

TABLE 431         ASIA PACIFIC: BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 338

TABLE 432        ASIA PACIFIC: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)          338

TABLE 433         ASIA PACIFIC: CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 338

TABLE 434         ASIA PACIFIC: BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)          339

TABLE 435         ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)          339

TABLE 436         ASIA PACIFIC: BIOMARKERS MARKET, BY RESEARCH AREA, 2022–2029 (USD MILLION)          339

TABLE 437         ASIA PACIFIC: BIOMARKERS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)     340

TABLE 438         ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)             340

TABLE 439         ASIA PACIFIC: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022–2029 (USD MILLION)             341

TABLE 440         ASIA PACIFIC: BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)     341

TABLE 441         ASIA PACIFIC: BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION) 342

13.4.2    CHINA  342

13.4.2.1 Rising incidence of CVD to propel market     342

TABLE 442         CHINA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)     343

TABLE 443         CHINA: CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)          343

TABLE 444         CHINA: BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)          343

TABLE 445         CHINA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 344

TABLE 446         CHINA: BIOMARKERS MARKET, BY RESEARCH AREA, 2022–2029 (USD MILLION) 344

TABLE 447         CHINA: BIOMARKERS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 344

TABLE 448         CHINA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)          345

TABLE 449         CHINA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022–2029 (USD MILLION)     345

TABLE 450         CHINA: BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 345

TABLE 451         CHINA: BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)          346

13.4.3    JAPAN  346

13.4.3.1 Stringent regulatory guidelines for drug discovery & development to propel market              346

TABLE 452         JAPAN: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)     347

TABLE 453         JAPAN: CONSUMABLES MARKET, BY TYPE, 022–2029 (USD MILLION)          347

TABLE 454         JAPAN: BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)          347

TABLE 455         JAPAN: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 348

TABLE 456         JAPAN: BIOMARKERS MARKET, BY RESEARCH AREA, 2022–2029 (USD MILLION) 348

TABLE 457         JAPAN: BIOMARKERS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 348

TABLE 458         JAPAN: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)          349

TABLE 459         JAPAN: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022–2029 (USD MILLION)     349

TABLE 460         JAPAN: BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 349

TABLE 461         JAPAN: BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)          350

13.4.4    INDIA   350

13.4.4.1 Favorable scenario for FDIs and increasing number of clinical trials to propel market   350

TABLE 462         INDIA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)     351

TABLE 463         INDIA: CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)          351

TABLE 464         INDIA: BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)          351

TABLE 465         INDIA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 352

TABLE 466         INDIA: BIOMARKERS MARKET, BY RESEARCH AREA, 2022–2029 (USD MILLION) 352

TABLE 467         INDIA: BIOMARKERS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 352

TABLE 468         INDIA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)          353

TABLE 469         INDIA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022–2029 (USD MILLION)     353

TABLE 470         INDIA: BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 353

TABLE 471         INDIA: BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)          354

13.4.5    SOUTH KOREA 354

13.4.5.1 Increasing innovations in NGS platforms to boost demand        354

TABLE 472         SOUTH KOREA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)       355

TABLE 473         SOUTH KOREA: CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 355

TABLE 474         SOUTH KOREA: BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 355

TABLE 475         SOUTH KOREA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)          356

TABLE 476         SOUTH KOREA: BIOMARKERS MARKET, BY RESEARCH AREA, 2022–2029 (USD MILLION)          356

TABLE 477         SOUTH KOREA: BIOMARKERS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)          356

TABLE 478         SOUTH KOREA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)       357

TABLE 479         SOUTH KOREA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022–2029 (USD MILLION)             357

TABLE 480         SOUTH KOREA: BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)          358

TABLE 481         SOUTH KOREA: BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)     358

13.4.6    AUSTRALIA       358

13.4.6.1 Growing demand for diagnostic solutions to support market growth        358

TABLE 482         AUSTRALIA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)          359

TABLE 483         AUSTRALIA: CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 359

TABLE 484         AUSTRALIA: BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)          359

TABLE 485         AUSTRALIA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)     360

TABLE 486         AUSTRALIA: BIOMARKERS MARKET, BY RESEARCH AREA, 2022–2029 (USD MILLION)     360

TABLE 487         AUSTRALIA: BIOMARKERS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)     360

TABLE 488         AUSTRALIA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)             361

TABLE 489         AUSTRALIA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022–2029 (USD MILLION)          361

TABLE 490         AUSTRALIA: BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)     362

TABLE 491         AUSTRALIA: BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION) 362

13.4.7    REST OF ASIA PACIFIC  362

TABLE 492         REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)       363

TABLE 493         REST OF ASIA PACIFIC: CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)          363

TABLE 494         REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)     364

TABLE 495         REST OF ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)             364

TABLE 496         REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY RESEARCH AREA, 2022–2029 (USD MILLION)            364

TABLE 497         REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)          365

TABLE 498         REST OF ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)   365

TABLE 499         REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022–2029 (USD MILLION)             366

TABLE 500         REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)           366

TABLE 501         REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)          367

13.5       LATIN AMERICA             367

13.5.1    LATIN AMERICA: RECESSION IMPACT   367

TABLE 502         LATIN AMERICA: BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     368

TABLE 503         LATIN AMERICA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)       368

TABLE 504         LATIN AMERICA: CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 368

TABLE 505         LATIN AMERICA: BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 369

TABLE 506         LATIN AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)          369

TABLE 507         LATIN AMERICA: BIOMARKERS MARKET, BY RESEARCH AREA, 2022–2029 (USD MILLION)          369

TABLE 508         LATIN AMERICA: BIOMARKERS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)          370

TABLE 509         LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)       370

TABLE 510         LATIN AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022–2029 (USD MILLION)             371

TABLE 511         LATIN AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)          371

TABLE 512         LATIN AMERICA: BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)     372

13.5.2    BRAZIL 372

13.5.2.1 Increased government investments in pharmaceutical R&D to drive market              372

TABLE 513         BRAZIL: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)     372

TABLE 514         BRAZIL: CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)          373

TABLE 515         BRAZIL: BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)          373

TABLE 516         BRAZIL: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 373

TABLE 517         BRAZIL: BIOMARKERS MARKET, BY RESEARCH AREA, 2022–2029 (USD MILLION) 374

TABLE 518         BRAZIL: BIOMARKERS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 374

TABLE 519        BRAZIL: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)          374

TABLE 520         BRAZIL: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022–2029 (USD MILLION)          375

TABLE 521         BRAZIL: BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 375

TABLE 522         BRAZIL: BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)          376

13.5.3    MEXICO             376

13.5.3.1 Rising demand for advanced healthcare services to support market growth              376

TABLE 523         MEXICO: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)          376

TABLE 524         MEXICO: CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)          377

TABLE 525         MEXICO: BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)          377

TABLE 526         MEXICO: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 377

TABLE 527         MEXICO: BIOMARKERS MARKET, BY RESEARCH AREA, 2022–2029 (USD MILLION)     378

TABLE 528         MEXICO: BIOMARKERS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 378

TABLE 529         MEXICO: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)             378

TABLE 530         MEXICO: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022–2029 (USD MILLION)          379

TABLE 531         MEXICO: BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 379

TABLE 532         MEXICO: BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)          380

13.5.4    REST OF LATIN AMERICA          380

TABLE 533         REST OF LATIN AMERICA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)            381

TABLE 534         REST OF LATIN AMERICA: CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)          381

TABLE 535         REST OF LATIN AMERICA: BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)          381

TABLE 536         REST OF LATIN AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)       382

TABLE 537         REST OF LATIN AMERICA: BIOMARKERS MARKET, BY RESEARCH AREA, 2022–2029 (USD MILLION)      382

TABLE 538         REST OF LATIN AMERICA: BIOMARKERS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)          383

TABLE 539         REST OF LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)   383

TABLE 540         REST OF LATIN AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022–2029 (USD MILLION)             384

TABLE 541         REST OF LATIN AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)           384

TABLE 542         REST OF LATIN AMERICA: BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)             385

13.6       MIDDLE EAST  385

13.6.1    MIDDLE EAST: RECESSION IMPACT       385

TABLE 543         MIDDLE EAST: BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION) 386

TABLE 544         MIDDLE EAST: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)       386

TABLE 545         MIDDLE EAST: CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 386

TABLE 546         MIDDLE EAST: BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 387

TABLE 547         MIDDLE EAST: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)          387

TABLE 548         MIDDLE EAST: BIOMARKERS MARKET, BY RESEARCH AREA, 2022–2029 (USD MILLION)          387

TABLE 549         MIDDLE EAST: BIOMARKERS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)          388

TABLE 550         MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)       388

TABLE 551         MIDDLE EAST: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022–2029 (USD MILLION)             389

TABLE 552         MIDDLE EAST: BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)     389

TABLE 553         MIDDLE EAST: BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION) 390

13.6.2    GCC COUNTRIES           390

TABLE 554         GCC COUNTRIES: BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     390

TABLE 555         GCC COUNTRIES: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)       391

TABLE 556         GCC COUNTRIES: CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)     391

TABLE 557         GCC COUNTRIES: BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 391

TABLE 558         GCC COUNTRIES: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)          392

TABLE 559         GCC COUNTRIES: BIOMARKERS MARKET, BY RESEARCH AREA, 2022–2029 (USD MILLION)          392

TABLE 560         GCC COUNTRIES: BIOMARKERS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)          393

TABLE 561        GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)       393

TABLE 562         GCC COUNTRIES: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022–2029 (USD MILLION)             394

TABLE 563         GCC COUNTRIES: BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)          394

TABLE 564         GCC COUNTRIES: BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)     395

13.6.2.1 Kingdom of Saudi Arabia   395

13.6.2.1.1            Growth in healthcare expenditure to boost demand     395

TABLE 565         KINGDOM OF SAUDI ARABIA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)            396

TABLE 566         KINGDOM OF SAUDI ARABIA: CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)             396

TABLE 567         KINGDOM OF SAUDI ARABIA: BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)          396

TABLE 568         KINGDOM OF SAUDI ARABIA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)    397

TABLE 569         KINGDOM OF SAUDI ARABIA: BIOMARKERS MARKET, BY RESEARCH AREA, 2022–2029 (USD MILLION)      397

TABLE 570         KINGDOM OF SAUDI ARABIA: BIOMARKERS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)          398

TABLE 571         KINGDOM OF SAUDI ARABIA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)   398

TABLE 572         KINGDOM OF SAUDI ARABIA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022–2029 (USD MILLION)           399

TABLE 573         KINGDOM OF SAUDI ARABIA: BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)           399

TABLE 574         KINGDOM OF SAUDI ARABIA: BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)             400

13.6.2.2 United Arab Emirates        400

13.6.2.2.1            Increasing collaborative efforts for pharmaceutical R&D to drive market              400

TABLE 575         UNITED ARAB EMIRATES: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)            401

TABLE 576         UNITED ARAB EMIRATES: CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)          401

TABLE 577         UNITED ARAB EMIRATES: BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)          401

TABLE 578         UNITED ARAB EMIRATES: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)       402

TABLE 579         UNITED ARAB EMIRATES: BIOMARKERS MARKET, BY RESEARCH AREA, 2022–2029 (USD MILLION)      402

TABLE 580         UNITED ARAB EMIRATES: BIOMARKERS MARKET BY TECHNOLOGY, 2022–2029 (USD MILLION)          403

TABLE 581         UNITED ARAB EMIRATES: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)   403

TABLE 582         UNITED ARAB EMIRATES: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022–2029 (USD MILLION)             404

TABLE 583         UNITED ARAB EMIRATES: BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)           404

TABLE 584         UNITED ARAB EMIRATES: BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)             405

13.6.2.3 Other GCC Countries        405

TABLE 585         OTHER GCC COUNTRIES: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)            406

TABLE 586         OTHER GCC COUNTRIES: CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)          406

TABLE 587         OTHER GCC COUNTRIES: BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)          406

TABLE 588         OTHER GCC COUNTRIES: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)             407

TABLE 589         OTHER GCC COUNTRIES: BIOMARKERS MARKET, BY RESEARCH AREA, 2022–2029 (USD MILLION)      407

TABLE 590         OTHER GCC COUNTRIES: BIOMARKERS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)          408

TABLE 591         OTHER GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)   408

TABLE 592         OTHER GCC COUNTRIES: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022–2029 (USD MILLION)             409

TABLE 593         OTHER GCC COUNTRIES: BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)           409

TABLE 594         OTHER GCC COUNTRIES: BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)             410

13.6.3    REST OF MIDDLE EAST 410

TABLE 595         REST OF MIDDLE EAST: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)   411

TABLE 596         REST OF MIDDLE EAST: CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)          411

TABLE 597         REST OF MIDDLE EAST: BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)     411

TABLE 598         REST OF MIDDLE EAST: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)             412

TABLE 599         REST OF MIDDLE EAST: BIOMARKERS MARKET, BY RESEARCH AREA, 2022–2029 (USD MILLION)            412

TABLE 600         REST OF MIDDLE EAST: BIOMARKERS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)          413

TABLE 601         REST OF MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)   413

TABLE 602         REST OF MIDDLE EAST: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022–2029 (USD MILLION)             414

TABLE 603         REST OF MIDDLE EAST: BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)           414

TABLE 604         REST OF MIDDLE EAST: BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)          415

13.7       AFRICA 415

13.7.1    INCREASING DEMAND FOR DRUG DISCOVERY & DEVELOPMENT TO SUPPORT MARKET GROWTH    415

TABLE 605         AFRICA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)          415

TABLE 606         AFRICA: CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)          416

TABLE 607         AFRICA: BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION)          416

TABLE 608         AFRICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 416

TABLE 609         AFRICA: BIOMARKERS MARKET, BY RESEARCH AREA, 2022–2029 (USD MILLION) 417

TABLE 610         AFRICA: BIOMARKERS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 417

TABLE 611        AFRICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)          417

TABLE 612         AFRICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022–2029 (USD MILLION)          418

TABLE 613         AFRICA: BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 418

TABLE 614         AFRICA: BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)          419

13.7.2    AFRICA: RECESSION IMPACT     419

14          COMPETITIVE LANDSCAPE       420

14.1       INTRODUCTION            420

14.2       KEY PLAYER STRATEGIES/RIGHT TO WIN          420

TABLE 615         OVERVIEW OF STRATEGIES DEPLOYED BY KEY BIOMARKER COMPANIES      420

14.3       REVENUE ANALYSIS      422

FIGURE 32         REVENUE ANALYSIS OF KEY PLAYERS, 2019–2023 (USD BILLION)           422

14.4       MARKET SHARE ANALYSIS         423

FIGURE 33         BIOMARKERS MARKET SHARE ANALYSIS, BY KEY PLAYER (2023)   423

TABLE 616         BIOMARKERS MARKET: DEGREE OF COMPETITION       423

14.5       BRAND/PRODUCT COMPARATIVE ANALYSIS    425

FIGURE 34         BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT & SERVICE            425

14.6       COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023   426

14.6.1    STARS  427

14.6.2    EMERGING LEADERS    427

14.6.3    PERVASIVE PLAYERS     427

14.6.4    PARTICIPANTS 427

FIGURE 35         BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 428

14.6.5    COMPANY FOOTPRINT ANALYSIS (KEY PLAYERS), 2023 429

FIGURE 36         BIOMARKERS MARKET: COMPANY FOOTPRINT 429

TABLE 617         BIOMARKERS MARKET: REGIONAL FOOTPRINT             430

TABLE 618         BIOMARKERS MARKET: PRODUCT & SERVICE FOOTPRINT              431

TABLE 619         BIOMARKERS MARKET: TECHNOLOGY FOOTPRINT      432

TABLE 620         BIOMARKERS MARKET: APPLICATION FOOTPRINT       433

14.7       COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023         434

14.7.1    PROGRESSIVE COMPANIES       434

14.7.2    RESPONSIVE COMPANIES          434

14.7.3    DYNAMIC COMPANIES 434

14.7.4    STARTING BLOCKS       434

FIGURE 37         BIOMARKERS MARKET: COMPANY EVALUATION MATRIX

(START-UPS/SMES), 2023           435

14.7.5    COMPETITIVE BENCHMARKING            436

TABLE 621         BIOMARKERS MARKET: DETAILED LIST OF KEY START-UPS/SMES         436

TABLE 622         BIOMARKERS MARKET: COMPETITIVE BENCHMARKING OF KEY START-UPS/SMES  437

14.8       VALUATION AND FINANCIAL METRICS OF BIOMARKER VENDORS              438

FIGURE 38         EV/EBITDA OF KEY VENDORS   438

FIGURE 39         YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 438

14.9       COMPETITIVE SCENARIO          439

14.9.1    PRODUCT/SERVICE LAUNCHES & APPROVALS 439

TABLE 623         BIOMARKERS MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2024 439

14.9.2    DEALS  440

TABLE 624         BIOMARKERS MARKET: DEALS, JANUARY 2021–APRIL 2024              440

14.9.3    EXPANSIONS    441

TABLE 625         BIOMARKERS MARKET: EXPANSIONS, JANUARY 2021–APRIL 2024      441

15          COMPANY PROFILES    442

(Business Overview, Products/Services Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*

15.1       KEY PLAYERS   442

15.1.1    F. HOFFMANN-LA ROCHE LTD. 442

TABLE 626         F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 442

FIGURE 40         F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)              443

TABLE 627         F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED          443

TABLE 628         F. HOFFMANN-LA ROCHE LTD.: PRODUCT/SERVICE LAUNCHES & APPROVALS         445

TABLE 629         F. HOFFMANN-LA ROCHE LTD.: DEALS 447

15.1.2    MERCK KGAA   449

TABLE 630         MERCK KGAA: COMPANY OVERVIEW    449

FIGURE 41         MERCK KGAA: COMPANY SNAPSHOT (2023)      450

TABLE 631         MERCK KGAA: PRODUCTS/SERVICES OFFERED 450

TABLE 632         MERCK KGAA: DEALS   454

TABLE 633         MERCK KGAA: EXPANSIONS      454

15.1.3    THERMO FISHER SCIENTIFIC INC.          455

TABLE 634         THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW              455

FIGURE 42         THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)   456

TABLE 635         THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED          457

TABLE 636         THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES & APPROVALS      461

TABLE 637         THERMO FISHER SCIENTIFIC INC.: DEALS          462

TABLE 638         THERMO FISHER SCIENTIFIC INC.: EXPANSIONS            463

15.1.4    QIAGEN             464

TABLE 639         QIAGEN: COMPANY OVERVIEW 464

FIGURE 43         QIAGEN: COMPANY SNAPSHOT (2023)  465

TABLE 640         QIAGEN: PRODUCTS/SERVICES OFFERED          465

TABLE 641         QIAGEN: PRODUCT/SERVICE APPROVALS         468

TABLE 642         QIAGEN: DEALS             468

15.1.5    ABBOTT            469

TABLE 643         ABBOTT: COMPANY OVERVIEW             469

FIGURE 44         ABBOTT: COMPANY SNAPSHOT (2023) 470

TABLE 644         ABBOTT: PRODUCTS/SERVICES OFFERED         470

TABLE 645         ABBOTT: PRODUCT/SERVICE APPROVALS        472

TABLE 646         ABBOTT: DEALS            472

15.1.6    AGILENT TECHNOLOGIES, INC.             473

TABLE 647         AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 473

FIGURE 45         AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)              474

TABLE 648         AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES OFFERED          474

TABLE 649         AGILENT TECHNOLOGIES, INC.: PRODUCT/SERVICE APPROVALS      476

TABLE 650         AGILENT TECHNOLOGIES, INC.: DEALS             476

15.1.7    REVVITY            478

TABLE 651         REVVITY: COMPANY OVERVIEW            478

FIGURE 46         REVVITY: COMPANY SNAPSHOT (2023) 479

TABLE 652         REVVITY: PRODUCTS/SERVICES OFFERED         479

TABLE 653         REVVITY: DEALS            482

15.1.8    CHARLES RIVER LABORATORIES            483

TABLE 654         CHARLES RIVER LABORATORIES: COMPANY OVERVIEW              483

FIGURE 47         CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2023)              484

TABLE 655         CHARLES RIVER LABORATORIES: PRODUCTS/SERVICES OFFERED          484

TABLE 656         CHARLES RIVER LABORATORIES: DEALS            485

15.1.9    BIO-RAD LABORATORIES, INC. 486

TABLE 657         BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW  486

FIGURE 48         BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023)              487

TABLE 658         BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED          487

TABLE 659         BIO-RAD LABORATORIES, INC.: PRODUCT/SERVICE LAUNCHES       489

TABLE 660         BIO-RAD LABORATORIES, INC.: DEALS 489

15.1.10  EUROFINS SCIENTIFIC  490

TABLE 661         EUROFINS SCIENTIFIC: COMPANY OVERVIEW  490

FIGURE 49         EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2023)    491

TABLE 662         EUROFINS SCIENTIFIC: PRODUCTS/SERVICES OFFERED              491

TABLE 663         EUROFINS SCIENTIFIC: DEALS  492

15.1.11  BIOMÉRIEUX    493

TABLE 664         BIOMÉRIEUX: COMPANY OVERVIEW     493

FIGURE 50         BIOMÉRIEUX: COMPANY SNAPSHOT (2023)       494

TABLE 665         BIOMÉRIEUX: PRODUCTS/SERVICES OFFERED 494

TABLE 666         BIOMÉRIEUX: PRODUCT/SERVICE APPROVALS 495

TABLE 667         BIOMÉRIEUX: DEALS    496

15.1.12  JSR CORPORATION       497

TABLE 668         JSR CORPORATION: COMPANY OVERVIEW        497

FIGURE 51         JSR CORPORATION: COMPANY SNAPSHOT (2023)          498

TABLE 669         JSR CORPORATION: PRODUCTS/SERVICES OFFERED    498

TABLE 670         JSR CORPORATION: DEALS       499

15.1.13  LABORATORY CORPORATION OF AMERICA HOLDINGS             500

TABLE 671         LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW  500

FIGURE 52         LABORATORY CORPORATION OF AMERICA HOLDINGS:

COMPANY SNAPSHOT (2023)    501

TABLE 672         LABORATORY CORPORATION OF AMERICA HOLDINGS:

PRODUCTS/SERVICES OFFERED            501

TABLE 673         LABORATORY CORPORATION OF AMERICA HOLDINGS:

PRODUCT/SERVICE LAUNCHES             502

TABLE 674         LABORATORY CORPORATION OF AMERICA HOLDINGS: DEALS  502

15.1.14  EKF DIAGNOSTICS        503

TABLE 675         EKF DIAGNOSTICS: COMPANY OVERVIEW         503

FIGURE 53         EKF DIAGNOSTICS: COMPANY SNAPSHOT (2022)           504

TABLE 676         EKF DIAGNOSTICS: PRODUCTS/SERVICES OFFERED     505

15.1.15  QUANTERIX      506

TABLE 677         QUANTERIX: COMPANY OVERVIEW      506

FIGURE 54         QUANTERIX: COMPANY SNAPSHOT (2023)        507

TABLE 678         QUANTERIX: PRODUCTS/SERVICES OFFERED  507

TABLE 679         QUANTERIX: PRODUCT LAUNCHES      508

TABLE 680         QUANTERIX: DEALS      508

15.1.16  MESO SCALE DIAGNOSTICS, LLC.          509

TABLE 681         MESO SCALE DIAGNOSTICS, LLC.: COMPANY OVERVIEW              509

TABLE 682         MESO SCALE DIAGNOSTICS, LLC.: PRODUCTS/SERVICES OFFERED          509

15.2       OTHER PLAYERS           511

15.2.1    CELERION         511

TABLE 683         CELERION: COMPANY OVERVIEW         511

15.2.2    STANDARD BIOTOOLS 512

TABLE 684         STANDARD BIOTOOLS: COMPANY OVERVIEW 512

15.2.3    SEBIA   513

TABLE 685         SEBIA: COMPANY OVERVIEW    513

15.2.4    BIOAGILITIX LABS         514

TABLE 686         BIOAGILITIX LABS: COMPANY OVERVIEW         514

15.2.5    STRESSMARQ BIOSCIENCES INC.            514

TABLE 687         STRESSMARQ BIOSCIENCES INC.: BUSINESS OVERVIEW 514

15.2.6    NORTHEAST BIOANALYTICAL LABORATORIES LLC.     515

TABLE 688         NORTHEAST BIOANALYTICAL LABORATORIES LLC.: BUSINESS OVERVIEW        515

15.2.7    SIGNOSIS, INC.  516

TABLE 689         SIGNOSIS, INC.: BUSINESS OVERVIEW   516

15.2.8    SERIMMUNE     517

TABLE 690         SERIMMUNE: COMPANY OVERVIEW      517

15.2.9    THERAINDX LIFESCIENCES PVT. LTD.  518

TABLE 691         THERAINDX LIFESCIENCES PVT. LTD.: COMPANY OVERVIEW              518

15.2.10  SYNEXA LIFE SCIENCES BV        519

TABLE 692         SYNEXA LIFE SCIENCES BV: COMPANY OVERVIEW         519

15.2.11  DIATECH PHARMACOGENETICS            520

TABLE 693         DIATECH PHARMACOGENETICS: COMPANY OVERVIEW              520

15.2.12  SINGULEX, INC. 521

TABLE 694         SINGULEX, INC.: COMPANY OVERVIEW 521

15.2.13  R-BIOPHARM AG            522

TABLE 695         R-BIOPHARM AG: COMPANY OVERVIEW            522

15.2.14  PROTEOME SCIENCES  523

TABLE 696         PROTEOME SCIENCES: COMPANY OVERVIEW   523

*Details on Business Overview, Products/Services Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

16          APPENDIX         524

16.1       DISCUSSION GUIDE      524

16.2       KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL             528

16.3       CUSTOMIZATION OPTIONS      530

16.4       RELATED REPORTS       531

16.5       AUTHOR DETAILS         532